Exchange: NASDAQ·Updated 04:46 PM EST

CRVS Earnings

Latest Earnings Results: Q3 '26

Reported: Nov 05

Estimated EPS

-$0.19

Reported EPS

-$0.22

Surprise

-14.33%

Estimated Rev

$0M

Reported Rev

---

Surprise

---

• Reported GAAP EPS of -$0.22 down -83.33% YoY • Corvus Pharmaceuticals expects its existing cash, cash equivalents and marketable securities to fund planned operating and capital needs into the second quarter of 2028, based on planned operations and cash flows.

Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q4 '26
-$0.23
--
--
N/A
Q3 '26
-$0.19
-$0.22
-14.33%
MISSED
Q2 '26
-$0.16
-$0.19
-19.40%
MISSED
Q1 '26
-$0.14
-$0.15
-5.32%
MISSED
Q4 '25
-$0.13
-$0.15
-15.89%
MISSED

Advertisement|Remove ads.